Treatment with istradefylline for postural abnormalities in Parkinson’s disease by Deutschländer, Angela B.
239www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Neurologia i Neurochirurgia Polska
Polish Journal of Neurology and Neurosurgery
2019, Volume 53, no. 4, pages: 239–241
DOI: 10.5603/PJNNS.2019.0038 
Copyright © 2019 Polish Neurological Society 
ISSN 0028–3843
INVITED EDITORIAL
Address for correspondence: Angela B. Deutschländer M.D., Ph.D., Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Rd S., Jacksonville,  
FL 32225, U.S.A. e-mail: Deutschlander.Angela@mayo.edu
Treatment with istradefylline for postural abnormalities in 
Parkinson’s disease
Angela B. Deutschländer
Department of Neurology, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL 32225, U.S.A.
AbstrAct
Introduction. In the current edition, Fujioka and colleagues report on four Japanese patients with Parkinson disease (PD) and seve-
re postural abnormalities treated with istradefylline (adenosine A2A receptor antagonist); further, dopamine agonists were with - 
drawn. Three patients experienced significant improvements of postural abnormalities. 
clinical reflections. Postural abnormalities in PD include camptocormia, antecollis, lateral trunk flexion, and scoliosis. They may 
be very pronounced and significantly reduce quality of life. The therapy of postural deformities in PD is currently disappointing. 
clinical implications. Effective therapeutic strategies for postural deformities in PD are an unmet need. Larger clinical trials 
investigating novel approaches including istradefylline are warranted.
(Neurol Neurochir Pol 2019; 53 (4): 239–241)
Istradefylline is a selective adenosine A2A receptor 
(A2AR) antagonist, which is approved for treatment in patients 
with Parkinson’s disease (PD) in Japan. It has been submitted 
for FDA approval for use as adjunctive treatment to L-dopa 
in patients with PD experiencing OFF episodes. Fujioka and 
colleagues describe four Japanese patients with PD and po-
stural abnormalities (antecollis, “Pisa syndrome”, and campto-
cormia), in whom treatment with istradefylline was initiated 
[1]. Further, their dopaminergic medication was discontinued 
simultaneously or up to two months before starting istradefyl-
line. Three patients had well-preserved paraspinal muscle 
volume and showed moderate to very good improvement 
of postural abnormalities. The fourth patient had moderate 
paraspinal muscle atrophy and experienced no improvement 
of her antecollis. In conclusion, istradefylline may be a novel 
therapeutic strategy for postural abnormalities in PD.
Postural abnormalities in Parkinson’s disease include 
camptocormia, antecollis, lateral trunk flexion (LTF, “Pisa syn-
drome”) and scoliosis. The term “camptocormia” was coined 
in 1915 [2]. The syndrome was initially described by Brodie in 
1937 as “hysterical bent back” [3]. Since consensus criteria for 
camptocormia are lacking, thoracolumbar flexion angles of ≥ 
45 degree are generally chosen for the diagnosis. Accordingly, 
the estimated prevalence of camptocormia varies (3–18%). 
Camptocormia and LTF are generally aggravated by walking 
or exercising and alleviated by lying supine, standing against 
a wall, using walking support, or in few instances by wearing 
a low-slung backpack, thus exhibiting features of dystonia, 
including a “sensory trick” [4, 5]. Scoliosis, however, remains 
fixed, and its diagnosis requires imaging of the spine [5]. Postu-
ral deformities are more frequent in female patients with PD, 
who are older, have more advanced disease, and they appear 
to occur more frequently in Asia. A recent study reported that 
9/18 patients with PD and postural deformities (≥ 1 point on 
the UPDRS III item “posture”; all patients were examined in 
the ON state) showed improved posture during istradefylline 
treatment. The patients who responded had higher Hoehn 
and Yahr stages [6]. A positive response to istradefylline was 
further observed in a case series, in which camptocormia was 
mostly OFF-state associated [7].  
The etiology of postural abnormalities in PD remains po-
orly understood [4, 5, 8]. Camptocormia in PD was reported to 
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worsen in the OFF state and thus suggested to arise due to rigi-
dity. Further etiologies of camptocormia include primary and 
secondary myopathy, proprioceptive dysregulation, dystonia, 
inflammation/myositis as well as functional and medication- 
induced disorders. Additionally, an impaired perception of ver-
ticality is associated with postural abnormalities in PD [4, 5, 8]. 
Medications that may cause postural abnormalities include 
dopamine agonists, anticholinergics, and amantadine. The 
notion that dopamine agonist may induce reversible postural 
abnormalities is currently based on case reports, which mostly 
stem from Japan [9–15]. L-dopa and dopaminergic agents may 
worsen, improve or not alter postural abnormalities in PD [4, 
16]. Finally, a consistent myopathic lesion pattern was seen 
in paraspinal muscle biopsies of patients with camptocormia 
and PD [17].
Transgenic mice with the DYT1 mutation showed reduced 
dopamine D2 receptor (D2R) protein and reduced ability 
of D2Rs to activate their cognate Go/i proteins. Resulting 
synaptic plasticity impairment was fully restored by pharma-
cological blockade of A2ARs [18]. Thus, istradefylline may 
improve dystonic components of postural abnormalities. 
Further, istradefylline may reduce rigidity by inhibiting basal 
ganglia output through an indirect pathway; it may reduce the 
cholinergic output of the pedunculopontine nucleus (PPN) 
[19–20]. The PPN is assumed to reduce muscle tone via α- and 
γ-motoneurons. Blockage of GABAergic nucleus accumbens 
output to brainstem centers including the mesencephalic 
locomotor region has also been postulated [21].
Current treatment of postural abnormalities in PD is 
challenging. Regarding injections with botulinum toxin i.m., 
differentiation between upper and lower camptocormia has 
been proposed [4], since different muscles appear involved 
in these two distinct types of camptocormia. In most studies, 
the rectus abdominis and the iliopsoas muscles were injected 
[4]. Some success was achieved using 1% lidocaine [22]. 
Other pharmacological options include trihexiphenidyl, baclo-
fen, amantadine, biperiden, tetrabenazine, clonazepam and bro-
mazepam; efficacy, however, is considered disappointing [4, 5 ,8]. 
L-dopa improved posture in about 20% of patients with PD 
[16]. One case series found that i.v. L-dopa infusions improved 
camptocormia and antecollis in PD, especially when abnormal 
postures were OFF-state associated [23]. Surgical approaches 
include deep brain stimulation (of about 80 patients, about 
60% showed improvement of posture); orthopedic spinal cor-
rection, and unilateral pallidotomy [8]. Lastly, physiotherapy 
can achieve improvements. 
Several randomized placebo-controlled studies inclu-
ding multicenter phase 3 studies (https://clinicaltrials.gov/), 
meta-analyses, and reviews [24–27] evaluating the efficacy of 
istradefylline in PD are available. Overall, istradefylline is con-
sidered to decrease OFF time duration and improve motor fe-
atures in PD. However, not all studies reported positive results 
[28]. Several studies found only moderate improvements. E.g., 
the KW-6002-US-2018 study showed only modest changes 
in UPDRS III scores, and istradefylline did not significantly 
impact OFF time duration [29]. One meta-analysis found 
positive results only for istradefylline 40 mg/d but not 20 mg/d 
[25]. In a recent post-marketing surveillance study, UPDRS 
III scores decreased from 33.7 to 29.2 after treatment over 
one year; OFF time duration was reduced in only 38.2% of the 
patients [30]. While adverse effects like dyskinesia or nausea 
do occur, istradefylline is generally considered well tolerated. 
In summary, postural abnormalities in PD can be very 
severe, and therapeutic strategies are an unmet need. Thus, 
larger clinical studies on therapeutic approaches are warran-
ted, both regarding surgical procedures and pharmacological 
approaches including novel agents like A2AR antagonists.
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